Friday, 29 June 2018

Altering chemotherapy improves outcomes in early-stage pancreatic cancer

The outlook for people diagnosed with early-stage pancreatic cancer can be expected to improve due to the results from two clinical trials. In the first trial, changing the type of chemotherapy given after surgery from a single drug to a multi-drug regimen greatly improved how long patients lived. Patients in the trial treated with the multi-drug regimen survived for an average of 4.5 years after treatment, substantially longer than expected.

To read more about the clinical trials, click here.



1 comment:

  1. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. I was exactly searching for. Thanks for such post and please keep it up. Great work. Pancreatic cancer

    ReplyDelete